Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Expenses (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Accumulated Expenses data on record, last reported at $150.3 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 26.12% year-over-year to $150.3 million; the TTM value through Sep 2025 reached $150.3 million, up 26.12%, while the annual FY2024 figure was $126.5 million, 86.29% up from the prior year.
  • Accumulated Expenses reached $150.3 million in Q3 2025 per AMPH's latest filing, up from $124.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $198.7 million in Q2 2023 and bottomed at $63.7 million in Q4 2022.
  • Average Accumulated Expenses over 5 years is $101.5 million, with a median of $81.9 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: surged 198.38% in 2023, then tumbled 49.96% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $67.3 million in 2021, then decreased by 5.33% to $63.7 million in 2022, then rose by 6.57% to $67.9 million in 2023, then soared by 86.29% to $126.5 million in 2024, then rose by 18.78% to $150.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $150.3 million in Q3 2025, $124.7 million in Q2 2025, and $123.1 million in Q1 2025.